DC
KYTH

Davenport & Co’s KYTHERA BIOPHARMACEUTICALS, INC COM KYTH Stock Holding History

Davenport & Co’s Portfolio KYTH Stock Details KYTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-18,816
Closed -$1.42M – 637
2015
Q2 		$1.42M Buy
+18,816
New +$1.01M 0.02% 244

Other funds holding KYTH

Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
GF
Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
WIC
Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
BM
Bridger Management New York $128M AUM 9.54% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return

Davenport & Co's KYTH Position: Q3 2015 in Review

Davenport & Co sold out of KYTHERA BIOPHARMACEUTICALS, INC COM (KYTH) in Q3 2015, closing a stake of 18,816 shares — an estimated $1.42M sold.

Davenport & Co first reported a position in KYTH in Q2 2015 and held it in 1 quarter. The position peaked at $1.42M in Q2 2015. 143 funds tracked by Wall St. Rank hold KYTH as of Q3 2015.

  • Davenport & Co reported no remaining KYTHERA BIOPHARMACEUTICALS, INC COM position as of Q3 2015 after selling out during the quarter.
  • Davenport & Co sold 18,816 KYTHERA BIOPHARMACEUTICALS, INC COM shares in Q3 2015, an estimated $1.42M.
  • Davenport & Co first reported a position in KYTHERA BIOPHARMACEUTICALS, INC COM in Q2 2015 and held it in 1 quarter.
  • Davenport & Co's KYTHERA BIOPHARMACEUTICALS, INC COM position peaked at $1.42M in Q2 2015.
  • 143 funds tracked by Wall St. Rank held KYTHERA BIOPHARMACEUTICALS, INC COM as of Q3 2015.

Based on Davenport & Co's 13F filing for Q3 2015, filed 23 Oct 2015.